Atlas Trials

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

Clinical trial NCT06705725 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06705725
Sponsor
Carbiogene Therapeutics Co. Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2024-12-26
Primary completion
2027-10-25
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.